(Q37445865)

20 August 2017

1 reference

title

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target (English)

1 reference

20 August 2017

1 reference

1 reference

Muzammil Ali

1

1 reference

20 August 2017

Mohammad Madjid

series ordinal

2

1 reference

20 August 2017

publication date

1 March 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

2

1 reference

20 August 2017

page(s)

159-173

1 reference

Phospholipase A(2) in vascular disease

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Anti-inflammatory properties of a platelet-activating factor acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Platelet-activating factor acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The phospholipase A2 superfamily and its group numbering system

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine induces the production of IL-1beta by human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Role of secretory and cytosolic phospholipase A(2) enzymes in lysophosphatidylcholine-stimulated monocyte arachidonic acid release

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine activates extracellular signal-regulated kinases 1/2 through reactive oxygen species in rat vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Endotoxins stimulate neutrophil adhesion followed by synthesis and release of platelet-activating factor in microparticles.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Infection and inflammation induce LDL oxidation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Hydrolysis and transesterification of platelet-activating factor by lecithin-cholesterol acyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Adenovirus-mediated gene transfer of human platelet-activating factor-acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Adenovirus-mediated gene transfer of Lp-PLA2 reduces LDL degradation and foam cell formation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Local expression of platelet-activating factor-acetylhydrolase reduces accumulation of oxidized lipoproteins and inhibits inflammation, shear stress-induced thrombosis, and neointima formation in balloon-injured carotid arteries in nonhyperlipidemic

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Platelet-activating factor acetylhydrolase, and not paraoxonase-1, is the oxidized phospholipid hydrolase of high density lipoprotein particles

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 (platelet-activating factor acetylhydrolase) and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 as a target of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Expression of G2A, a receptor for lysophosphatidylcholine, by macrophages in murine, rabbit, and human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Impaired clearance of apoptotic cells promotes synergy between atherogenesis and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Mildly oxidised LDL induces more macrophage death than moderately oxidised LDL: roles of peroxidation, lipoprotein-associated phospholipase A2 and PPARgamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Apoptotic cells as sources for biologically active oxidized phospholipids

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Phagocytosis of apoptotic cells by macrophages is impaired in atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The isoprostanes: unique products of arachidonic acid oxidation-a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Localization of distinct F2-isoprostanes in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine increases expression of heparin-binding epidermal growth factor-like growth factor in human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Endocytic uptake of lysophosphatidylcholine mediated by macrophage scavenger receptor plays a major role in oxidized low density lipoprotein-induced macrophage growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The phospholipase-A2 reaction leads to increased monocyte adhesion of endothelial cells via the expression of adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Alteration of lysophosphatidylcholine content in low density lipoprotein after oxidative modification: relationship to endothelium dependent relaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine induces early growth response factor-1 expression and activates the core promoter of PDGF-A chain in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine increases the secretion of matrix metalloproteinase 2 through the activation of NADH/NADPH oxidase in cultured aortic endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lysophosphatidylcholine inhibits endothelium-dependent hyperpolarization and N omega-nitro-L-arginine/indomethacin-resistant endothelium-dependent relaxation in the porcine coronary artery.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Serum levels of type II secretory phospholipase A2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 for early risk stratification in patients with suspected acute coronary syndrome: a multi-marker approach: the North Wuerttemberg and Berlin Infarction Study-II (NOBIS-II).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lack of association between carotid intima-media thickness and PAF-acetylhydrolase mass and activity in patients with primary hyperlipidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The effect of statin therapy on lipoprotein associated phospholipase A2 levels

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infar

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein-associated phospholipase A2 in patients with coronary heart disease versus control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Fluvastatin slow-release lowers platelet-activating factor acetyl hydrolase activity: a placebo-controlled trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Functional impairment of two novel mutations detected in lipoprotein-associated phospholipase A2 (Lp-PLA2) deficiency patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Platelet-activating factor-acetylhydrolase and PAF-receptor gene haplotypes in relation to future cardiovascular event in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The identification of clinical candidate SB-480848: a potent inhibitor of lipoprotein-associated phospholipase A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, dou

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Association between Lp-PLA2 and coronary artery disease: Focus on its relationship with lipoproteins and markers of inflammation and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Elevated secretory non-pancreatic type II phospholipase A2 serum activity is associated with impaired endothelial vasodilator function in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796678.5.2.159

21 January 2018

Identifiers

DOI

10.2217/14796678.5.2.159

1 reference

20 August 2017

1 reference